De-Escalation of Axillary Surgery: A Review of Choosing Wisely Guideline Evidence

guideline advises against routine sentinel lymph node biopsy in women ≥ 70 years with clinically node-negative, hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer receiving endocrine therapy. Across studies, omission of sentinel lymph node biopsy in appropriately selected patients is associated with low axillary recurrence rates without compromise in disease-free, breast cancer-specific, or overall survival. Although regional recurrence is modestly increased without axillary staging, these events are uncommon and typically amenable to salvage therapy. Despite strong evidence and professional endorsement, implementation of this recommendation remains inconsistent, with persistently high utilization of sentinel lymph node biopsy among women eligible for omission. Contemporary data indicate that adjuvant therapy decisions in hormone receptor-positive disease are driven primarily by tumor biology, with nodal status altering management in a minority of postmenopausal women. We propose a structured clinical decision framework incorporating tumor biology, physiologic rather than chronological age, competing mortality risk, and planned endocrine therapy. When nodal status is unlikely to influence treatment, omission of sentinel lymph node biopsy is a safe, evidence-based refinement that reduces morbidity without compromising survival. Multidisciplinary coordination is essential to optimize adjuvant therapy while minimizing low-value surgical care.